Background

Descending thoracic aorta aneurysm (dTAA) has increasing incidence and, if left untreated, could lead to death. There is not any study of satralizumab treatment for preventing dTAA formation and progression.

Materials and Methods

Forty male 10-week-old Rattus norvegicus were enrolled in the experiment. They were divided into four equal groups: dTAA treated with saline (dTAA-P) and dTAA treated with satralizumab (dTAA-S). One of the control groups was treated with saline (C-P), and the other was treated with satralizumab (C-S). Satralizumab and saline were used once every 2 weeks, subcutaneously 120 mg for 4 weeks. dTA diameter was measured at days 0, 3, 7, 14, 21, and 28.

Results

IL-6 level was measured on the 7th day that showed significantly increased IL-6 serum level in dTAA-P rats compared to C-P. Maximal dTA diameter (%MAD) was obtained at day 14, which was scientifically matched to the aorta aneurysm definition (>50% increase in diameter). From the seventh day, a significant difference in %MAD was observed between dTAA-P and dTAA-S groups. However, the %MAD of these two groups was significantly higher than control groups till the end of the 28th day.

Conclusion

Using an IL-6 inhibitor agent to prevent dTAA formation and progression showed promising results. It suggests that using the IL-6 inhibitors in susceptible persons can be considered a lifesaving therapeutic approach.

中文翻译：

---

Satralizumab，用于预防胸降主动脉瘤发展的新型白细胞介素 6 抑制剂

背景

胸降主动脉瘤 (dTAA) 的发病率越来越高，如果不及时治疗，可能会导致死亡。没有任何关于 satralizumab 治疗预防 dTAA 形成和进展的研究。

材料和方法

40 只 10 周大的雄性褐家鼠参加了实验。他们被分成四个相等的组：用盐水 (dTAA-P) 治疗的 dTAA 和用 satralizumab (dTAA-S) 治疗的 dTAA。一个对照组用生理盐水 (CP) 治疗，另一个用 satralizumab (CS) 治疗。每 2 周使用一次 Satralizumab 和生理盐水，皮下注射 120 mg，持续 4 周。在第 0、3、7、14、21 和 28 天测量 dTA 直径。

结果

在第 7 天测量 IL-6 水平，表明与 CP 相比，dTAA-P 大鼠的 IL-6 血清水平显着增加。在第 14 天获得最大 dTA 直径 (%MAD)，这与主动脉瘤定义科学匹配（直径增加 >50%）。从第七天开始，在 dTAA-P 和 dTAA-S 组之间观察到 %MAD 的显着差异。然而，直到第 28 天结束时，这两组的 %MAD 明显高于对照组。

结论

使用 IL-6 抑制剂来防止 dTAA 的形成和进展显示出有希望的结果。这表明在易感人群中使用 IL-6 抑制剂可以被认为是一种挽救生命的治疗方法。